𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma

✍ Scribed by Ji-Youn Han; Dae Ho Lee; Sung Young Lee; Chun Gun Park; Hyae Young Kim; Hong Gi Lee; Jae Jin Lee; Heung Tae Kim; Jin Soo Lee

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
115 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch

A Phase II trial of gemcitabine and doce
A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma
✍ Irina E. Popa; Kathleen Stewart; Frederick P. Smith; Naiyer A. Rizvi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The goals of the current study were to determine the safety and efficacy of a nonplatinum‐containing doublet, gemcitabine and docetaxel, in the treatment of patients with chemotherapy‐naive nonsmall cell lung carcinoma (NSCLC). ## METHODS Thirty‐two patients with advanc

Randomized Phase II study of two opposit
Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Hyeong-Seok Lim; Dae Ho Lee; So Young Ju; Sung Young Lee; Hyae Youn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract ## BACKGROUND Combined chemotherapy with irinotecan and cisplatin (IP) is active in patients with nonsmall cell lung carcinoma (NSCLC). However, the optimal administration schedule needs to be defined to maximize its synergic effect. The authors evaluated the efficacy, toxicity, and ph

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p